Investors Purchase High Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the target of some unusual options trading on Wednesday. Stock traders purchased 4,572 call options on the stock. This is an increase of 725% compared to the average volume of 554 call options.

Ventyx Biosciences Trading Up 2.0%

VTYX stock opened at $2.49 on Friday. The stock’s 50 day simple moving average is $1.44 and its 200 day simple moving average is $1.75. The stock has a market capitalization of $177.19 million, a PE ratio of -1.06 and a beta of 0.85. Ventyx Biosciences has a 12-month low of $0.78 and a 12-month high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. On average, research analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Institutional Trading of Ventyx Biosciences

A number of institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. boosted its holdings in shares of Ventyx Biosciences by 12.4% during the 4th quarter. American Century Companies Inc. now owns 67,329 shares of the company’s stock valued at $147,000 after acquiring an additional 7,414 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Ventyx Biosciences by 23.3% in the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company’s stock worth $90,000 after acquiring an additional 7,768 shares during the period. Barclays PLC grew its holdings in shares of Ventyx Biosciences by 14.2% in the fourth quarter. Barclays PLC now owns 91,669 shares of the company’s stock worth $200,000 after acquiring an additional 11,374 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Ventyx Biosciences by 76.0% in the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company’s stock worth $59,000 after acquiring an additional 11,543 shares during the period. Finally, Palumbo Wealth Management LLC grew its holdings in shares of Ventyx Biosciences by 97.1% in the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock worth $52,000 after acquiring an additional 11,792 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.